GHSR-1a is a novel pro-angiogenic and anti-remodeling target in rats after myocardial infarction

European Journal of Pharmacology

Volumn 788, Issue , 2016, Pages 218-225

  Yuan, Ming Jie ^a   Wang, Tao ^b   Kong, Bin ^a   Wang, Xin ^a   Huang, Cong Xin ^a   Wang, Danny ^b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Angiogenesis; Cardiac remodeling; GHSR 1a; Myocardial infarction

Indexed keywords

ADENOVIRUS VECTOR; GHRELIN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MESSENGER RNA; PROTEIN KINASE B; SMALL INTERFERING RNA; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC MUSCLE; CARDIAC REMODELING; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; HEART DISEASE; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION; HEART INFARCTION SIZE; HEART VENTRICLE SIZE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCAR; SURVIVAL RATE; UMBILICAL VEIN ENDOTHELIAL CELL; VIRAL GENE THERAPY; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; ENDOTHELIUM CELL; GENETICS; HEART VENTRICLE; HEART VENTRICLE REMODELING; METABOLISM; MOLECULARLY TARGETED THERAPY; MYOCARDIAL INFARCTION; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; SURVIVAL ANALYSIS;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ENDOTHELIAL CELLS; HEART VENTRICLES; HUMANS; MALE; MOLECULAR TARGETED THERAPY; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PHYSIOLOGIC; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GHRELIN; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR REMODELING;

EID: 84978105208     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2016.06.032     Document Type: Article

References (34)

1. Bagno, L.L., Kanashiro-Takeuchi, R.M., Suncion, V.Y., Golpanian, S., Karantalis, V., Wolf, A., Wang, B., Premer, C., Balkan, W., Rodriguez, J., Valdes, D., Rosado, M., Block, N.L., Goldstein, P., Morales, A., Cai, R.Z., Sha, W., Schally, A.V., Hare, J.M., Growth hormone-releasing hormone agonists reduce myocardial infarct scar in swine with subacute ischemic cardiomyopathy. J. Am. Heart Assoc., 4, 2015.
2. Beiras-Fernandez, A., Kreth, S., Weis, F., Ledderose, C., Pottinger, T., Dieguez, C., Beiras, A., Reichart, B., Altered myocardial expression of ghrelin and its receptor (GHSR-1a) in patients with severe heart failure. Peptides 31 (2010), 2222–2228.
3. Casanueva, F.F., Camina, J.P., Carreira, M.C., Pazos, Y., Varga, J.L., Schally, A.V., Growth hormone-releasing hormone as an agonist of the ghrelin receptor GHS-R1a. Proc. Natl. Acad. Sci. USA 105 (2008), 20452–20457.
4. Cheng, Y., Jiang, S., Hu, R., Lv, L., Potential mechanism for endothelial progenitor cell therapy in acute myocardial infarction: activation of VEGF- PI3K/Akte-NOS pathway. Ann. Clin. Lab. Sci. 43 (2013), 395–401.
5. DeBoer, M.D., The use of ghrelin and ghrelin receptor agonists as a treatment for animal models of disease: efficacy and mechanism. Curr. Pharm. Des. 18 (2012), 4779–4799.
6. Delporte, C., Structure and physiological actions of ghrelin. Scientifica, 2013, 2013, 518909.
7. Florea, V., Majid, S.S., Kanashiro-Takeuchi, R.M., Cai, R.Z., Block, N.L., Schally, A.V., Hare, J.M., Rodrigues, C.O., Agonists of growth hormone-releasing hormone stimulate self-renewal of cardiac stem cells and promote their survival. Proc. Natl. Acad. Sci. USA 111 (2014), 17260–17265.
8. Giacca, M., Zacchigna, S., VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond. Gene Ther. 19 (2012), 622–629.
9. Huang, C.X., Yuan, M.J., Huang, H., Wu, G., Liu, Y., Yu, S.B., Li, H.T., Wang, T., Ghrelin inhibits post-infarct myocardial remodeling and improves cardiac function through anti-inflammation effect. Peptides 30 (2009), 2286–2291.
10. Jernberg, T., Hasvold, P., Henriksson, M., Hjelm, H., Thuresson, M., Janzon, M., Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur. Heart J. 36 (2015), 1163–1170.
11. Kanashiro-Takeuchi, R.M., Szalontay, L., Schally, A.V., Takeuchi, L.M., Popovics, P., Jaszberenyi, M., Vidaurre, I., Zarandi, M., Cai, R.Z., Block, N.L., Hare, J.M., Rick, F.G., New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget 6 (2015), 9728–9739.
12. Kanashiro-Takeuchi, R.M., Takeuchi, L.M., Rick, F.G., Dulce, R., Treuer, A.V., Florea, V., Rodrigues, C.O., Paulino, E.C., Hatzistergos, K.E., Selem, S.M., Gonzalez, D.R., Block, N.L., Schally, A.V., Hare, J.M., Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI). Proc. Natl. Acad. Sci. USA 109 (2012), 559–563.
13. Khatib, M.N., Shankar, A., Kirubakaran, R., Agho, K., Simkhada, P., Gaidhane, S., Saxena, D., B U, Gode, D., Gaidhane, A., Zahiruddin, S.Q., Effect of ghrelin on mortality and cardiovascular outcomes in experimental rat and mice models of heart failure: a systematic review and meta-analysis. PLoS One, 10, 2015, e0126697.
14. Khatib, M.N., Simkhada, P., Gode, D., Cardioprotective effects of ghrelin in heart failure: from gut to heart. Heart Views 15 (2014), 74–76.
15. Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., Kangawa, K., Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402 (1999), 656–660.
16. Lacerda-Miranda, G., Soares, V.M., Vieira, A.K., Lessa, J.G., Rodrigues-Cunha, A.C., Cortez, E., Garcia-Souza, E.P., Moura, A.S., Ghrelin signaling in heart remodeling of adult obese mice. Peptides 35 (2012), 65–73.
17. Latet, S.C., Hoymans, V.Y., Van Herck, P.L., Vrints, C.J., The cellular immune system in the post-myocardial infarction repair process. Int. J. Cardiol. 179 (2015), 240–247.
18. Li, Y., Chen, C., Yao, F., Su, Q., Liu, D., Xue, R., Dai, G., Fang, R., Zeng, J., Chen, Y., Huang, H., Ma, Y., Li, W., Zhang, L., Liu, C., Dong, Y., AMPK inhibits cardiac hypertrophy by promoting autophagy via mTORC1. Arch. Biochem Biophys. 558 (2014), 79–86.
19. Mao, Y., Tokudome, T., Kishimoto, I., Ghrelin as a treatment for cardiovascular diseases. Hypertension 64 (2014), 450–454.
20. Montalescot, G., Brieger, D., Dalby, A.J., Park, S.J., Mehran, R., Duration of dual antiplatelet therapy after coronary stenting: a review of the evidence. J. Am. Coll. Cardiol. 66 (2015), 832–847.
21. Novakova, V., Sandhu, G.S., Dragomir-Daescu, D., Klabusay, M., Apelinergic system in endothelial cells and its role in angiogenesis in myocardial ischemia. Vasc. Pharm. 76 (2016), 1–10.
22. Pradhan, G., Samson, S.L., Sun, Y., Ghrelin: much more than a hunger hormone. Curr. Opin. Clin. Nutr. Metab. Care 16 (2013), 619–624.
23. Ruozi, G., Bortolotti, F., Falcione, A., Dal Ferro, M., Ukovich, L., Macedo, A., Zentilin, L., Filigheddu, N., Gortan Cappellari, G., Baldini, G., Zweyer, M., Barazzoni, R., Graziani, A., Zacchigna, S., Giacca, M., AAV-mediated in vivo functional selection of tissue-protective factors against ischaemia. Nat. Commun., 6, 2015, 7388.
24. Sabate, M., Windecker, S., Iniguez, A., Okkels-Jensen, L., Cequier, A., Brugaletta, S., Hofma, S.H., Raber, L., Christiansen, E.H., Suttorp, M., Pilgrim, T., Anne van Es, G., Sotomi, Y., Garcia-Garcia, H.M., Onuma, Y., Serruys, P.W., Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur. Heart J. 37 (2016), 229–240.
25. Sudar Milovanovic, E., Jovanovic, A., Misirkic-Marjanovic, M., Vucicevic, L., Janjetovic, K., Isenovic, E.R., Effects of Intracerebroventricularly (ICV) injected ghrelin on cardiac inducible nitric oxide synthase activity/expression in obese rats. Exp. Clin. Endocrinol. Diabetes 123 (2015), 581–588.
26. Tian, X., Pu, W.T., Zhou, B., Cellular origin and developmental program of coronary angiogenesis. Circ. Res. 116 (2015), 515–530.
27. Tokudome, T., Kishimoto, I., Miyazato, M., Kangawa, K., Ghrelin and the cardiovascular system. Front Horm. Res. 43 (2014), 125–133.
28. Wang, L., Chen, Q., Li, G., Ke, D., Ghrelin ameliorates impaired angiogenesis of ischemic myocardium through GHSR1a-mediated AMPK/eNOS signal pathway in diabetic rats. Peptides 73 (2015), 77–87.
29. Wang, X., Wang, X.L., Chen, H.L., Wu, D., Chen, J.X., Wang, X.X., Li, R.L., He, J.H., Mo, L., Cen, X., Wei, Y.Q., Jiang, W., Ghrelin inhibits doxorubicin cardiotoxicity by inhibiting excessive autophagy through AMPK and p38-MAPK. Biochem Pharm. 88 (2014), 334–350.
30. Yin, Y., Li, Y., Zhang, W., The growth hormone secretagogue receptor: its intracellular signaling and regulation. Int. J. Mol. Sci. 15 (2014), 4837–4855.
31. Yuan, M.J., He, H., Hu, H.Y., Li, Q., Hong, J., Huang, C.X., Myocardial angiogenesis after chronic ghrelin treatment in a rat myocardial infarction model. Regul. Pept. 179 (2012), 39–42.
32. Yuan, M.J., Huang, H., Quan, L., Tang, Y.H., Wang, X., Jiang, H., Huang, C.X., Expression of ghrelin and its receptor in rats after coronary artery ligation. Regul. Pept. 192–193 (2014), 1–5.
33. Zhang, M., Fang, W.Y., Qu, X.K., Yuan, F., Wang, W.G., Fei, J., Wang, Z.G., AMPK activity is down-regulated in endothelial cells of GHS-R(-/-) mice. Int. J. Clin. Exp. Pathol. 6 (2013), 1770–1780.
34. Zhu, C., Qi, X., Chen, Y., Sun, B., Dai, Y., Gu, Y., PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer. J. Cancer Res. Clin. Oncol. 137 (2011), 1587–1594.